Application of cepharanthine in preparing medicine for resisting SARS virus

Abstract

A kind of application of Stephalin in the preparation of anti-SARS virus medicine. The anti-SARS virus medicine is prepared with Stephalin as an active ingredient. Within the safe dose range, the inhibition rate of SARS virus is high; it has a strong effect of preventing SARS virus infection. Function; fast recovery, can reduce the symptoms of infected patients; drug toxicity is small, good stability, strong drug resistance.

Description

technical field

[0001] The present invention relates to the field of medicines, in particular to the application of stepherin in the preparation of anti-SARS virus medicines. Background technique

[0002] Since the formal identification of the pathogen of atypical pneumonia as the SARS coronavirus, great progress has been made in the prevention and research of atypical pneumonia and its pathogen, and the development of anti-SARS coronavirus drugs and vaccines is also in full swing. SARS virus is a new type of coronavirus with strong infectivity and variability. At present, there is still a lack of effective treatment for SARS. The current treatment includes antiviral treatment such as ribavirin, serum therapy, etc., hormones are used to reduce the damage of the immune system to the lungs, antibiotics are used to treat potential bacterial infections, and syndrome differentiation of integrated traditional Chinese and Western medicine; The application of ventilator and the sym...

Examples

Embodiment 1

[0037] 1. Experimental materials The drug to be tested is stephadin, which is made into a suspension with physiological saline for the experiment.

[0038] 2. Experimental animals Kunming mice, body weight (20±2) g; Wistar rats, body weight (270±20) g; C57BL / 6 mice, body weight (20±2) g.

[0039] 3. Acute and chronic toxicity test of oral gavage administration ① Determination of acute toxicity (LD50) and maximum tolerated dose in mice: 30 animals that had been fasted for 12 hours in advance were randomly divided into 3 groups, 10 in each group , the distance between each dose group was 0.85. The stephenicine was made into concentrations of (2.0, 1.7, 1.4%) respectively, and then the animals were given 0.4ml·10g-1 body weight, 1 time ig, the maximum dose was 800mg·kg-1, observed for 1 week, and the general condition of all animals Good, without any toxic reaction and death. On this basis, carry out the maximum tolerance test within 1 day; take another 20 animals, half male an...

Embodiment 2

[0041] In the clinical trial conducted on human beings, the test group took medication, and the usage and dosage of Stephania injection: 50 mg once a day, slowly intravenously drip. The control group injected normal saline, its state of illness is as shown in table 3, and the healing time is as shown in table 4:

[0042] Table 3: Condition Status

[0043] Group n Reduced Stable Increased Ridit test

[0044] Test group 30 19 8 3(0)

[0045] Control group 28 2 16 10(2) P<0.05

[0046] The results in this table show that the patients in the test group (that is, the treatment group using RD-01) have a greater reduction in the condition than the patients in the control group.

[0047] Table 4: Healing Time

[0048] Group n Shortened Basically unchanged Extended Ridit test

[0049] Test group 30 21 7 2

[0050] Control group 28 3 10 17(2) P<0.05

[0051] Note: The numbers in () are the death toll.

[0052] The results in this table show...

technical field

[0001] The present invention relates to the field of medicines, in particular to the application of stepherin in the preparation of anti-SARS virus medicines. Background technique

[0002] Since the formal identification of the pathogen of atypical pneumonia as the SARS coronavirus, great progress has been made in the prevention and research of atypical pneumonia and its pathogen, and the development of anti-SARS coronavirus drugs and vaccines is also in full swing. SARS virus is a new type of coronavirus with strong infectivity and variability. At present, there is still a lack of effective treatment for SARS. The current treatment includes antiviral treatment such as ribavirin, serum therapy, etc., hormones are used to reduce the damage of the immune system to the lungs, antibiotics are used to treat potential bacterial infections, and syndrome differentiation of integrated traditional Chinese and Western medicine; The application of ventilator and the sym...

Examples

Embodiment 1

[0037] 1. Experimental materials The drug to be tested is stephadin, which is made into a suspension with physiological saline for the experiment.

[0038] 2. Experimental animals Kunming mice, body weight (20±2) g; Wistar rats, body weight (270±20) g; C57BL / 6 mice, body weight (20±2) g.

[0039] 3. Acute and chronic toxicity test of oral gavage administration ① Determination of acute toxicity (LD50) and maximum tolerated dose in mice: 30 animals that had been fasted for 12 hours in advance were randomly divided into 3 groups, 10 in each group , the distance between each dose group was 0.85. The stephenicine was made into concentrations of (2.0, 1.7, 1.4%) respectively, and then the animals were given 0.4ml·10g-1 body weight, 1 time ig, the maximum dose was 800mg·kg-1, observed for 1 week, and the general condition of all animals Good, without any toxic reaction and death. On this basis, carry out the maximum tolerance test within 1 day; take another 20 animals, half male an...

Embodiment 2

[0041] In the clinical trial conducted on human beings, the test group took medication, and the usage and dosage of Stephania injection: 50 mg once a day, slowly intravenously drip. The control group injected normal saline, its state of illness is as shown in table 3, and the healing time is as shown in table 4:

[0042] Table 3: Condition Status

[0043] Group n Reduced Stable Increased Ridit test

[0044] Test group 30 19 8 3(0)

[0045] Control group 28 2 16 10(2) P<0.05

[0046] The results in this table show that the patients in the test group (that is, the treatment group using RD-01) have a greater reduction in the condition than the patients in the control group.

[0047] Table 4: Healing Time

[0048] Group n Shortened Basically unchanged Extended Ridit test

[0049] Test group 30 21 7 2

[0050] Control group 28 3 10 17(2) P<0.05

[0051] Note: The numbers in () are the death toll.

[0052] The results in this table show...

Images